Lupin Launches first peptide-based injectable, Ganirelix Acetate Injection in the United States
Global pharma major Lupin Limited (Lupin) announced the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Ganirelix is Lupin’s first peptide-based injectable, strengthening the Company’s commitment to innovative healthcare solutions
Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC. It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate Injection had estimated annual sales of USD 87 million in the U.S. (IQVIA MAT December 2023).
